

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Loxapine inhalation for the treatment of acute agitation and disturbed behaviours associated with schizophrenia or bipolar disorder

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

Consultees highlighted that the incidence of schizophrenia and bipolar disorder is higher in specific groups. In addition, consultees suggested that patients with reduced capacity should be appropriately considered in the appraisal.
--

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal. Any evidence received in patients with reduced capacity will be presented to the Appraisal Committee.
--

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director: Elisabeth George

Date: 30 05 12